Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC

Recruiting now · Phase 1

Conditions studied: Arrhythmogenic Right Ventricular Cardiomyopathy

In brief

This first-in-human study is designed to evaluate the safety, and preliminary efficacy (PD) of TN-401 gene therapy in adult patients with symptomatic PKP2 mutation-associated ARVC.

Key facts

Study ID
NCT06228924
Run by
Tenaya Therapeutics
People needed
15
Starts
2024-03-26
Expected to finish
2029-10-01
Last updated by the study team
2025-02-06

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.